RETIFANLIMAB VS AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA: A COST-UTILITY ANALYSIS IN ITALY

被引：0
|
作者：
Ghetti, G. [1 ]
Porta, C. [1 ]
Povero, M. [1 ]
Trimarchi, C. [2 ]
机构：
[1] AdRes HE, Turin, Italy
[2] Incyte Biosci Italy, Milan, MI, Italy
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE65
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] A cost-utility analysis of avelumab for metastatic Merkel cell carcinoma in Taiwan
    Chang, Wen-Cheng
    Lin, Amy Y.
    Hsu, Jason C.
    Wu, Chiao-En
    Goh, Connie
    Chou, Patrick
    Kuo, Kaitlin
    Chang, Anne
    Palencia, Roberto
    CANCER REPORTS, 2021, 4 (06)
  • [2] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Bullement, Ash
    Nathan, Paul
    Willis, Anna
    Amin, Amerah
    Lilley, Cameron
    Stapelkamp, Ceilidh
    Hatswell, Anthony
    Pescott, Chris
    Bharmal, Murtuza
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 377 - 390
  • [3] Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
    Ash Bullement
    Paul Nathan
    Anna Willis
    Amerah Amin
    Cameron Lilley
    Ceilidh Stapelkamp
    Anthony Hatswell
    Chris Pescott
    Murtuza Bharmal
    PharmacoEconomics - Open, 2019, 3 : 377 - 390
  • [4] Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
    Tereza Lanitis
    Irina Proskorovsky
    Apoorva Ambavane
    Matthias Hunger
    Ying Zheng
    Murtuza Bharmal
    Hemant Phatak
    Advances in Therapy, 2019, 36 : 2327 - 2341
  • [5] Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
    Lanitis, Tereza
    Proskorovsky, Irina
    Ambavane, Apoorva
    Hunger, Matthias
    Zheng, Ying
    Bharmal, Murtuza
    Phatak, Hemant
    ADVANCES IN THERAPY, 2019, 36 (09) : 2327 - 2341
  • [6] COST-EFFECTIVENESS OF AVELUMAB IN THE TREATMENT OF PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN PORTUGAL
    Pinheiro, B.
    Silva Miguel, L.
    Alarcao, J.
    Palencia, R.
    Borges, M.
    VALUE IN HEALTH, 2020, 23 : S432 - S432
  • [7] Retifanlimab in metastatic Merkel cell carcinoma in first line
    Zucman-Rossi, Clara
    Boussemart, Lise
    BULLETIN DU CANCER, 2024, 111 (10) : 906 - 908
  • [8] BUDGET IMPACT ANALYSIS OF AVELUMAB IN PATIENTS WITH METASTATIC MERKEL CELL CARCINOMA IN THE US
    Bharmal, M.
    D'Angelo, S. P.
    Phatak, H.
    VALUE IN HEALTH, 2017, 20 (09) : A424 - A424
  • [9] Avelumab for the treatment of metastatic Merkel cell carcinoma
    Cordes, L. M.
    Gulley, J. L.
    DRUGS OF TODAY, 2017, 53 (07) : 377 - 383
  • [10] Avelumab: A Review in Metastatic Merkel Cell Carcinoma
    Shirley, Matt
    TARGETED ONCOLOGY, 2018, 13 (03) : 409 - 416
12345